Margarida Maia, PhD, science writer —

A committee of the European Medicines Agency (EMA) has accepted for review GSK’s marketing authorization application for Blenrep (belantamab mafodotin) to be used as part of a combination treatment for people with relapsed or refractory multiple myeloma (RRMM). The Committee for Medicinal Products for Human Use (CHMP) will…

Through its Myeloma Investment Fund, the Multiple Myeloma Research Foundation (MMRF) has invested $1 million in novel CAR T-cell technology from Dynamic Cell Therapies (DCT) that aims to better treat multiple myeloma. Backed by this investment, DCT remains on track to move a new CAR T-cell…

A Phase 3 clinical trial evaluating the safety and efficacy of AbbVie’s experimental therapy ABBV-383 in adults with relapsed or refractory multiple myeloma (RRMM) has treated its first patient. Called CERVINO (NCT06158841), the study plans to enroll up to 380 patients, ages 18 and older, at…

A unanimous vote by a committee of the U.S. Food and Drug Administration (FDA) could lead to an early outcome measure — one known as minimal residual disease, or MRD negativity — being used for accelerated approval of treatments in clinical trials of…

Health Canada has granted conditional approval to Pfizer’s Elrexfio (elranatamab-bcmm), expanding the list of countries where the medication can be used for adults with multiple myeloma whose cancer has returned and who have not responded to previous treatment. The conditional approval, officially a Notice of Compliance, will require…

Bristol Myers Squibb has received a positive opinion from an arm of the European Medicines Agency (EMA) on the use of its CAR T-cell therapy Abecma (idecabtagene vicleucel) in earlier lines of treatment for relapsed and hard-to-treat multiple myeloma. Abecma already is approved in the European Union…

AstraZeneca is set to buy Gracell Biotechnologies in a deal worth up to $1.2 billion that would add GC012F — an experimental dual-targeting CAR T-cell therapy being developed for multiple myeloma and other hematologic or blood-borne cancers — to the buyer’s pipeline. CAR T-cell therapy works…

The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma who received at least prior three lines of therapy and whose cancer has worsened since their last therapy. The indication covers patients on all 27 countries of the European Union,…

A study has observed a rise in the number of new cases of myeloma in both men and women in the U.S. since the turn of the century, with the steepest increases seen among young Hispanic women. The incidence, or number of new cases diagnosed each year, of myeloma…

The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of ISB 2001, Ichnos Sciences’ trispecific antibody — a treatment that simultaneously targets three proteins. This study (NCT05862012) aims to recruit up to 80 adults with relapsed or…